Latest filing published 19 Aug 2016 for VivoSim Labs, INC..
Insider track record
No signal scores available.
Mark Kessel: trading record in brief
Mark Kessel discloses dealings in 3 companies, chiefly Oncotelic Therapeutics, Inc., Dynavax Technologies Corp and VivoSim Labs, Inc. We count 9 filings; the first trade dates from 20 July 2009 and the latest from 17 August 2016.
Sales make up the whole of the open-market record (1 sale, €21.7M). Outside the open market, there are 6 share grants.
On 19 August 2016 came the latest disclosure, a share grant in VivoSim Labs, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Mark Kessel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,500 shares0Common StockSEC:0001209191-16-138011:0
- 7,500 shares0Common StockSEC:0001209191-16-138011:1
- 6,000,000 shares@ US$4.73Common Stock, par value $0.001 per shareSEC:0001104659-12-069632:0
- 690,631 sharesCommon Stock, par value $0.001 per shareSEC:0001181431-10-022219:0
- 10,000,000 shares@ US$1.25Common Stock, par value $0.01 per shareSEC:0001181431-09-036047:0
5 of 5 declarations
